retatrutide side effects trial results Lilly orforglipron oral GLP-1 phase 3 weight loss Retatrutide TRANSCEND-T2D-1 topline results are

Semaglutide is a medication originally developed for type 2 diabetes that is now increasingly used for weight management due to its proven benefits on appetite control and metabolism

Change one amino acid, cleave one bond, oxidize one residue, and the entire three-dimensional structure shifts

Major Stories Washington State investigators found serious violations at a Mochi Health-affiliated compounding pharmacy producing GLP-1s, and a med spa bill in Indiana hears public testimony about a med spa bill

As retatrutide remains unlicensed in the UK and is not approved by the MHRA or EMA, it is only accessible through regulated clinical trials

Retatrutide has no approved version and has never appeared on the shortage list, so the exemption never applied

These drugs have significance in obesity treatment, particularly in situations where more broadly acting medications are not suitable for the patient